10.25
Capricor Therapeutics Inc (CAPR) 最新ニュース
US FDA’s Top Cell and Gene Therapy Regulators Forced Out - insights.citeline.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor - Bluefield Daily Telegraph
Capricor gets FDA's Orphan Drug status for muscle disorder therapy - MSN
Capricor Therapeutics Announces Orphan Drug Designation for - GlobeNewswire
Capricor Therapeutics (CAPR) Rating Reiterated by Roth Capital | CAPR Stock News - GuruFocus
Capricor Therapeutics (CAPR) Gains FDA Orphan Drug Status for Deramiocel - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc.CAPR - PR Newswire
Capricor Therapeutics' Deramiocel Wins FDA Orphan Drug Designation for Becker Muscular Dystrophy - MarketScreener
Capricor Therapeutics (CAPR) Receives Orphan Drug Designation for BMD Treatment | CAPR Stock News - GuruFocus
Capricor Scores Double Win: FDA Orphan Drug Status for Becker MD Plus DMD Approval Progress - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor ... - Eagle-Tribune
FDA Grants Orphan Status to Capricor's Becker Muscular Dystrophy Treatment (CAPR) | CAPR Stock News - GuruFocus
Capricor Therapeutics (CAPR) Shares Dip Seen as Buying Opportuni - GuruFocus
Capricor Therapeutics (CAPR) Sees Unusual Put Activity | CAPR St - GuruFocus
Capricor (CAPR) Shares Decline Amid FDA Advisory Panel Developments | CAPR Stock News - GuruFocus
Capricor Therapeutics (CAPR) Receives Buy Rating from HC Wainwri - GuruFocus
Capricor Therapeutics (CAPR) Receives Buy Rating from HC Wainwright & Co. | CAPR Stock News - GuruFocus
Capricor Therapeutics (CAPR) Shares Drop After FDA Withdraws Mee - GuruFocus
Capricor gets Form 483 from FDA; WuXi Biologics’ new China factory - Endpoints News
Capricor says FDA inspection brought Form 483 with several observations - Yahoo Finance
Capricor Therapeutics (CAPR) Manufacturing Facility Cleared by F - GuruFocus
Capricor Therapeutics (CAPR) Shares Decline Amid FDA Inspection Report - GuruFocus
Capricor Therapeutics (CAPR) Advances Deramiocel Approval Proces - GuruFocus
Capricor: A Hold Rating With Regulatory FDA Form Given For Deramiocel Advancement (CAPR) - Seeking Alpha
Capricor Therapeutics Announces Key Regulatory Updates for its D - GuruFocus
FDA Completes Inspection of Capricor Therapeutics Manufacturing Facility For Deramiocel Approval: Retail Sees ‘Unimaginable Potential’ - Asianet Newsable
Capricor Therapeutics (CAPR) Manufacturing Facility Cleared by FDA | CAPR Stock News - GuruFocus
Capricor Therapeutics' Duchenne Therapy Facility Inspection Completed by FDA - MarketScreener
Capricor falls after facility inspection related to deramiocel - Seeking Alpha
Capricor Therapeutics stock falls after FDA inspection of manufacturing facility - Investing.com Australia
Capricor Therapeutics stock falls after FDA inspection of manufacturing facility By Investing.com - Investing.com Nigeria
Capricor’s DMD therapy clears FDA pre-license inspection By Investing.com - Investing.com Canada
Capricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program - GlobeNewswire
Capricor's DMD Drug Hits 3 Major FDA Milestones: Advisory Committee Set for July 30 - Stock Titan
Cantor Fitzgerald Estimates CAPR FY2026 Earnings - Defense World
Behind the Scenes of Capricor Therapeutics's Latest Options Trends - Benzinga
(CAPR) Trading Signals - news.stocktradersdaily.com
Wellington Management Group LLP Purchases New Position in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor Therapeutics Sees Unusually High Options Volume (NASDAQ:CAPR) - Defense World
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Capricor Therapeutics, Inc.CAPR - FinancialContent
Capricor Therapeutics (CAPR) Sees Borrow Rate Surge | CAPR Stock News - GuruFocus
Millennium Management LLC Acquires 12,285 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
BNP Paribas Financial Markets Reduces Stake in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor Therapeutics, Inc. (CAPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Two Sigma Investments LP Has $1.64 Million Stake in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Bank of America Corp DE Purchases 154,127 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Bronstein, Gewirtz & Grossman, LLC Encourages Capricor Therapeutics, Inc. (CAPR) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Capricor Therapeutics, Inc. (CAPR) And Encourages Shareholders to Connect - ACCESS Newswire
Capricor Therapeutics Inc (NASDAQ:CAPR) Shares Bought by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
Deutsche Bank AG Takes Position in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Capricor Therapeutics, Inc. (CAPR) And Encourages Shareholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Capricor Therapeutics, Inc. (CAPR) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
(CAPR) Technical Data - news.stocktradersdaily.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Capricor Therapeutics, Inc. (CAPR) and Encourages Investors to Learn More About the Investigation - Louisiana First News
Capricor Therapeutics, Inc. (CAPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
大文字化:
|
ボリューム (24 時間):